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Abstract  
Background and aims: In cirrhotic patients with renal failure, renal blood flow 
autoregulation curve is shifted to the right, which is consequent upon sympathetic 
nervous system activation and endothelial dysfunction. Albumin infusion improves 
renal function in cirrhosis by mechanisms that are incompletely understood. We 
aimed to determine the effect of albumin infusion on systemic hemodynamics, 
renal blood flow, renal function and endothelial function in patients with acute 
decompensation of cirrhosis and acute kidney injury.  
Methods: Twelve patients with refractory ascites and 10 patients with acute 
decompensation of cirrhosis and acute kidney injury were studied. Both groups 
were treated with intravenous albumin infusion, 40-60 g/d over 3-4 days. Cardiac 
and renal hemodynamics were measured. Endothelial activation/dysfunction was 
assessed using von Willebrand factor and serum nitrite levels. F2α Isoprostanes, 
resting neutrophil burst and noradrenaline levels were quantified as markers of 
oxidative stress, endotoxemia and sympathetic activation respectively. 
Results: Albumin infusion lead to a shift in the renal blood flow autoregulation 
curve towards normalization, which resulted in a significant increase in renal blood 
flow. Accordingly, improvement of renal function was observed. In parallel, a 
significant decrease in sympathetic activation, inflammation/oxidative stress and 
endothelial activation/dysfunction was documented. Improvement of renal blood 
flow correlated with improvement in endothelial activation (r=0.741, p<0.001).   
Conclusions: The data suggest that albumin infusion improves renal function in 
acutely decompensated cirrhotic patients with acute kidney injury by impacting on 
renal blood flow autoregulation. This is possibly achieved through endothelial 
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stabilisation, and a reduction in the sympathetic tone, endotoxemia and oxidative 
stress. 
Key words: liver cirrhosis, albumin, endothelial dysfunction, renal blood flow, acute 
kidney injury, refractory ascites, human 
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Introduction 
 Advanced liver failure is characterized by hemodynamic alterations initiated by 
portal hypertension and splanchnic vasodilation. In advanced cirrhosis, systemic 
vascular resistance (SVR) is markedly reduced and mean arterial pressure (MAP) 
is maintained through the activation of compensatory mechanisms (renin-
angiotensin system, sympathetic nervous system and arginine-vasopressin 
hormone) (1). Bacterial translocation (2) and bacterial infections (3) are factors that 
may further deteriorate this impaired circulatory state.  
 Endothelial cells regulate vascular tone and modulate blood flow towards different 
organs by synthesizing agonist and antagonist in response to different stimuli. 
Bacterial products (4), inflammatory mediators (5) and reactive oxygen species (6) 
may activate endothelial cells and induce endothelial activation (EA) and 
dysfunction (ED). These factors are frequently present in cirrhosis, and correlate 
with progression of the disease (7). Renal blood flow (RBF) is tightly regulated to 
ensure a relatively stable renal perfusion regardless of daily fluctuations in MAP. 
Sympathetic activation is involved in this regulation (8). Other factors such as renin-
angiotensin system (9), inflammatory mediators and other as yet unidentified factors 
have been implicated in this RBF/RPP (renal perfusion pressure) relationship (10). It 
has been shown that the RBF autoregulation curve (curve linking between RPP and 
RBF) shifts progressively to the right in cirrhosis, according to the severity of the liver 
failure and the degree of sympathetic activation (11). Thus, RBF becomes 
progressively dependent on RPP.  
 Progressive hypoalbuminaemia is a common feature of cirrhosis. Recent studies 
have suggested that albumin is also functionally impaired in cirrhotic patients and 
associated with the higher risk mortality (12). Infusion of human serum albumin 
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prevents and improves renal dysfunction in cirrhotic patients (13-17). The exact 
mechanism through which these effects are seen is unclear. Understanding those 
mechanisms may help identify possible new pharmacological approaches in 
patients with renal failure and those at risk. Most studies suggest that this is 
consequent upon amelioration in the activated renin-angiotensin system. In patients 
with spontaneous bacterial peritonitis, albumin infusion resulted in a reduction in von 
Willebrand factor (vWF) and nitric oxide levels suggesting that it may improve ED (18).  
 Renal failure in cirrhosis, particularly hepatorenal syndrome is associated with 
extremely poor prognosis(19). A significant number of patients with acute 
decompensation of cirrhosis (AD) does not fulfill criteria for the diagnosis of 
hepatorenal syndrome (20) and they are classified as having acute kidney injury 
(AKI) (21). Although a lot is known about the pathophysiologic basis of effect of 
albumin infusion in patients with hepatorenal syndrome, its effects in patients with 
AD and associated AKI are not clear. 
 The aim of this study was to further understand the pathophysiological and clinical 
effects of albumin infusion in AD patients with AKI. Specifically, we sought to 
evaluate the effect of albumin infusion on systemic and renal hemodynamics, RBF 
autoregulation and endothelial function and, further investigate related mechanisms 
that might be implicated in the regulation of RBF using a group of patients with 
refractory ascites (RA) as controls.  
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Patients and Methods  
Ethical considerations 
The local ethics committee approved the study and the patients who took part gave 
their informed consent. The present study is a part of studies in patients with acute 
decompensation of cirrhosis recruited into observational and interventional studies 
following a prospective assessment (22-24). A retrospective analysis of this data was 
performed in this study. 
Patients 
Twenty-two patients with clinical, biochemical, radiological and/or histological 
evidence of liver cirrhosis and controls in different studies over 5 years (2001-
2006) were grouped into 2 different categories. The first group included patients 
(n=12) with chronic decompensation of cirrhosis due to refractory ascites (RA 
group). The second group of patients (n=10) recruited subjects with AKI in the 
setting of an acute decompensation of previously stable liver disease due to a 
precipitating event (AKI group). AD for this study was defined as a worsening in 
liver function over a period of 2 to 4 weeks manifested by increasing jaundice (> 
100 µmol/L) and AKI. AKI was defined as a rise in serum creatinine of ≥50% from 
baseline or a rise of serum creatinine by ≥26.4 mmol/l in <48 h (21). The 
precipitating factor associated to the AD and AKI was acute alcoholic hepatitis 
(n=7) or active infection (n=3). These patients received supportive therapy 
including treatment for the developed complications and organ failure according to 
the local protocols (corticosteroids if they had severe alcoholic hepatitis defined by 
Maddrey index above 32 and antibiotics if they had sepsis). None of these patients 
with AKI fulfilled the specific criteria for type I hepatorenal syndrome, therefore 
were not treated with vasoconstrictors. Patients were excluded if they were under 
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18 or over 80 years of age, in case of pregnancy, had hepatic/extrahepatic 
malignancy, active gastrointestinal bleeding, if they received vasoactive treatment 
(β-blockers, renin-angiotensin-aldosterone system inhibitors), immunomodulatory 
therapy or albumin infusion prior to entry in the study. Basal characteristics of the 
patients are summarized in table 1. 
Design 
Patients with RA who agreed to take part in the study were admitted to the hospital 
and a radial artery and venous catheter were placed. A baseline blood sample was 
collected after 30 minutes of lying supine for further determinations. A hemodynamic 
study was performed at baseline, which included cardiac hemodynamics, hepatic 
venous pressure gradient (HVPG) measurement and RBF.  All patients received 40-
60 grams/day of albumin during 3-4 days and were again tested for hemodynamics 
and blood determination after the treatment (1 day after finalizing albumin therapy). 
Hormonal Assays 
Norepinephrine was measured using high-performance liquid chromatography and 
electrochemical detection (normal plasma concentration: 0-5 nmol/L). 
Cytokines 
IL-6 determination was performed using commercially available set (BioSource 
International, Belgium).  
Respiratory Burst 
The neutrophil functional study (an index of endotoxemia) was performed as 
previously described (25). Whole blood from healthy volunteers was layered over 5 
mL of Polymorphprep (Axis-Shield, Norway) and spun (30 min, 400g, room 
temperature). Neutrophils were harvested from the second interface and washed 
with phosphate buffered saline. Neutrophils were counted and re-suspended in 
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PBS at a density of 5x105 in 50 μL; 50 μL of cell suspension and 50μL of plasma 
were used per assay. Viability (Trypan blue) was over 98%. The Phagoburst kit 
(Orpegen Pharma, Germany) was used to determine the percentage of 
neutrophils that produce reactive oxidants.  Briefly, 100 μl of heparinized whole 
blood or 50μL of isolated neutrophils and 50 μL of plasma were incubated for 20 
min with either 20 μl of opsonized Escherichia coli (2 x 107 bacteria) or without 
stimulus at 37 °C. The formation of reactive oxidants was monitored by the 
oxidation of dihydrorhod- amine 123 to rhodamine. To identify neutrophils, cells 
were stained with anti–CD16-PE antibody (Immuntools, Germany) and analyzed 
by fluorescence-activated cell sorting (Becton Dickinson FACS Canto II, FACS 
Diva 6.0 software, CA). Neutrophils were gated and the percentage of CD16-
positive cells producing reactive oxygen metabolites calculated. 
F2 Isoprostanes  
F2 isoprostanes (free 8-isoprostane F2) were assayed with an EIA kit (Cayman 
Chemical, Ann Arbor, MI) according to the manufacturer’s instructions (26). Briefly, 
200 μl plasma was deproteinized with ethanol containing 3H -prostaglandin E2 as 
an internal standard to account for losses. After centrifugation, the supernatant 
was dried, and 2 mL acetic acid was added and applied to a preconditioned C18 
SPE cartridge (Waters, Milford, MA). The column was washed with water, dried, 
and eluted with high-performance liquid chromatography–grade hexane. The 
prostanoid fraction was eluted with 5 ml ethylacetate containing 1% methanol, 
eluant reduced to dryness and reconstituted in 450 μl of EIA buffer, 100 μl being 
used to determine recovery of 3H-PGE2 and 50 μl added to the EIA plate with 
isoprostane tracer and antibody. Isoprostane levels were determined by reference 
to authentic standards and corrected for losses. 
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Malondialdehyde  
Malondialdehyde (MDA) was measured using a modified thiobarbituric acid 
reactive substance assay described by Lapenna (12) wherein the major interfering 
component in the plasma is inhibited by addition of sodium sulphate. 
Von Willebrand Factor assay 
Plasma levels of vWF were assessed by in-house Enzime-Linked Immunoassay.  
Nitrite-nitrate levels  
Nitrite and nitrate were determined by a modiﬁed Greiss test  and as previously 
described (27). 
Ischemia-modified albumin 
Ischemia-modified albumin (IMA) was determined according to the cobalt-binding 
assay method(28). Briefly, plasma was incubated with a cobalt chloride (1 g/L, 10 
minutes) and dithiothreitol (1.5 g/L, 2 minutes) before dilution in saline prior to 
measurement at 470 nm (Agilent 8453 Diode Array, Agilent, UK). IMA was 
calculated from the difference between samples measured with and without 
dithiothreitol. Plasma albumin concentration was determined (COBAS Integra, 
Roche, UK) and IMA/albumin ratio was calculated (IMAR).  
Haemodynamic assessment  
Cardiac hemodynamics: Heart rate (HR), oxygen saturation, and 
electrocardiographic activity were recorded continuously. MAP was measured 
before and every 5 minutes after catheterization (model 86S; Hewlett Packard, 
CA). The pulmonary artery was catheterized using a Swan-Ganz catheter (Edward 
Life Sciences, CA) and cardiac output calculated using thermodilution method 
(Edwards Life Sciences). Each measurement was performed in triplicate, and the 
mean was calculated. 
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HVPG: the right hepatic vein was cannulated using a balloon-tipped catheter 
(Cordis, The Netherlands) under fluoroscopic guidance (SA-900U; Toshiba, 
Japan), and wedged measurements were made in triplicate (Omnipaque; 
Amersham Health, England). Careful attention ensured a wedged position. HVPG 
was calculated as the difference between the wedged and free hepatic venous 
pressures. 
Measurement of RBF: Primed continuous infusion of para-aminohippuric acid 
(Sigma, England) was used to measure renal plasma flow using the Fick principle 
with simultaneous sampling of an artery and the renal vein 1 hour after starting the 
infusion. For para-aminohippuric acid determinations, 500 μl plasma was added to 
50 μl trichloroacetic acid solution (50% wt/vol). Plasma para-aminohippuric acid 
concentration was determined spectrophotometrically. RBF was calculated as 
follow (11): 
Calculations: 
1. Renal plasma flow(mL/min) was calculated as:  
             PAH infusion rate x [PAH] infused 
RPF=  _____________________________ 
             [PAH] arterial - [PAH] renal vein  
2. RBF (mL/min) was calculated as: 
                 RPF 
RBF=  _________ 
                 1-hematocrit 
3. RPP (mmHg) was calculated as: 
     RPP = MAP – inferior vena cava pressure 
4. Systemic vascular resistance (dynes/sec X cm-5) was calculated as: 
           79.9 X (MAP-central venous pressure) 
SVR= _______________________________ 
                                          cardiac output 
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Mathematical model of RBF autoregulation 
A mathematical model was used to extrapolate the shape of the autoregulation 
curves from clinical measurements in each patient group (full description of the 
model is published(11)). Briefly, the model made simple physiological assumptions 
to link renal blood flow with renal perfusion pressure and a parameter α indicating 
the severity of autoregulation failure. The full model equation is: 
Renal  Blood  Flow = k  RPP5(1-
a(RPP+a)2
b2 + (RPP+a)2
)4  
where a = 0.95, b = 40.9 and k = 8.2x10-5. The parameter α was estimated by 
employing a best fit approach which used measurements of RBF and RPPs.  A 
value of α=0 represented a healthy state, whereas an increase in α indicated a 
worsening of the state.  
Statistical analysis 
Continuous variables are expressed as mean±SD or median (interquartile range). 
Normality of continuous variables was explored using the Shapiro-Wilk Test. 
Depending on the distribution of the variables, parametric or nonparametric tests 
were applied to study the within-subject (t test for paired samples or Wilcoxon test) 
or between-group (Student t test or Mann-Whitney rank-sum test) differences. The 
Pearson or Spearman correlation coefficient tests were used to assess 
correlations between variables. P value < 0.05 was considered statistically 
significant. Calculations were performed with Graphpad Prism 5.
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Results 
The patients included in this study received the dose of albumin in accordance with 
the study protocol and no significant major adverse effects were observed.  
Renal function and biochemical changes 
In this study we assessed renal function using different parameters (table 2). 
Patients with AKI had a higher plasma creatinine concentration (213±60.3 vs 
94.8±13.3 μmol/L, p<0.001) and lower creatinine clearance (13±4.2 vs 29.3±7.1 
mL/min, p<0.001) at baseline compared to patients with RA. Both groups showed a 
significant improvement of renal function following albumin treatment. Similarly, 
plasma sodium concentration and urinary sodium excretion increased in both 
groups. Patients with AKI had a marked sympathetic activation, which was 
significantly greater than in patients with RA (norepinephrine 8.2±2.1 vs 3.6±0.5 
nmol/L, p<0.0001). A significant amelioration was observed in both groups. 
Albumin concentration and function 
Regarding to plasma albumin, albumin infusion increased plasma concentration 
and improve albumin function (IMAR) in both groups of patients (table 2). 
Systemic, Cardiac, Renal and Hepatic Hemodynamics 
The data on hemodynamics is summarized in table 3. Patients with RA had 
decreased SVR (normal range 1600-2400 dynes/s/cm5) with the other parameters of 
cardiac hemodynamics within the normal values. They also exhibited lower RBF 
compared to the reference population (1000-1250 mL/min). After albumin infusion 
there was an increase in central venous pressure, MAP and RPP, together with an 
improvement in the RBF.   
Patients with AKI showed worse hemodynamic state at baseline with lower SVR 
(p=0.014), MAP (p<0.001), RPP (p<0.001) and higher HR (p=0.004) compared to 
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patients with RA. Albumin infusion was associated with a significant improvement in 
the hyperdynamic circulation (increase in SVR and MAP and decrease in CO and 
HR). This was associated with a significant improvement in RBF.  
In addition, no worsening in hepatic vein portal pressure gradient was observed 
following albumin administration. To the contrary, a significant decrease in the HVPG 
was observed in the subset of patients with AKI. 
Impact of albumin infusion on RBF autoregulation 
Renal autoregulation curves were estimated for both groups of patients before and 
after receiving albumin (Fig 1). AKI group exhibited a more impaired renal 
autoregulation with a more pronounced shift towards the right and a more marked 
loss in its sigmoid shape compared to patients with RA. In both RA and AKI 
groups, administration of albumin shifted the autoregulation curves towards the 
left, which denotes an improvement in the renal blood-flow autoregulation. 
Endothelial function 
Since endothelial cells modulate blood flow to different organs we conducted an 
endothelial assessment in these patients before and after albumin infusion. EA was 
assessed by measuring plasma levels of vWF. Plasma concentration of nitrate and 
nitrite were indicators of ED. Patients with AKI showed significantly higher plasma 
levels of vWF (463±73 vs 342±68, p=0.001), nitrate (82±26 vs 42±18, p<0.001) and 
nitrite (8±2 vs 4±1, p<0.001) before receiving albumin indicating more marked 
EA/ED (table 2). Both groups of patients exhibited a significant decrease in vWF, 
nitrate and nitrite following albumin treatment denoting an improvement in 
endothelial function (Fig 2). Interestingly, we observed that an increase in RBF 
following albumin infusion closely correlated with a decrease in the vWF a (r=0.741, 
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p<0.001), indicating that a rise in RBF is concomitant with improvement in 
endothelial activation (Fig 3).  
Inflammation and oxidative stress markers 
Since endotoxemia, inflammation and oxidative stress are factors able to induce 
EA/ED we investigated these conditions. Patients with AKI had higher endotoxemia 
level (% neutrophil burst 52±20 vs 37±13, p=0.04) compared to patients with RA. 
Albumin infusion was associated with a significant decrease in the neutrophil burst 
(ΔRA 12±10%, p<0.01; ΔAKI 17±12%, p<0.01). Accordingly, there was also a 
decrease in oxidative stress markers in both groups. Patients with RA exhibited a 
significant reduction in MDA and those with AKI showed a decrease in MDA and 
F2 isoprostanes levels (Fig 4). There were no significant changes in plasma levels 
of IL-6. 
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Discussion 
This study shows for the first time that albumin infusion shifts the abnormal RBF 
autoregulation curve in the patients with RA and in those with AD and AKI to the 
left allowing greater renal blood flow for a given RPP. This shift was associated 
with an improvement of renal function. This improvement was demonstrable by an 
increase in albumin content and function, a reduction in inflammatory markers and 
oxidative stress, which together contributed to an improvement in endothelial 
function. We also make the novel observation that a measurable change in 
albumin function can be achieved with albumin infusion. 
RBF autoregulation in cirrhotic patients with refractory ascites and hepatorenal 
syndrome has been shown to be progressively shifted to the right with advancing 
liver disease and worsening of renal function (11) and correlates with the severity of 
sympathetic activation. This study extends these observations to patients with AD 
and AKI where more severe liver disturbance was observed. This observation has 
clinical implications since RBF and ultimately renal function become completely 
dependent on the RPP.  
The current understanding of the pathophysiology of renal dysfunction in 
advanced liver failure is that the relative systemic hypovolemia due to portal 
hypertension and splanchnic vasodilation activates compensatory mechanisms 
such as sympathetic nervous system and renin-angiotensin-aldosterone system(1). 
Additional factors may deteriorate this hemodynamic scenario such as bacterial 
traslocation (2), bacterial infections (3) and oxidative stress (29) leading to renal 
failure and increased mortality(30). These abnormalities are common and 
progressive with the severity of the disease (31, 32).  
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Recent studies indicate that not only albumin concentration but also albumin 
function is progressively reduced in cirrhosis (12). Albumin has demonstrated its 
ability to improve and prevent renal dysfunction in liver failure (13-17). It has been 
generally accepted that its benefit relied on its oncotic properties. However, recent 
advances in the knowledge of albumin structure and function have disclosed non-
oncotic potential benefits of albumin(18). 
In agreement with these previous studies, we found that albumin infusion 
improved renal function in patients with refractory ascites and in those with AD 
and AKI. HRS type-1, a more severe form of renal failure was not investigated in 
this study since its optimum management requires additional vasoactive 
treatments. Interestingly, the hemodynamic assessment showed that albumin 
improves RBF even without significant changes in RPP, and increase SVR. The 
mathematical model reflects that albumin modifies the autoregulation curve 
towards normalization, suggesting that for a given RPP there is an improvement in 
RBF. Among the mechanisms modulating the RBF there are those that impact on 
renal arteriolar resistance. It is known that sympathetic activation alters renal 
vascular tone via α1-adrenergic mechanism in experimental models(33). This is 
supported by the improvement in renal function following lumbar sympathectomy 
in cirrhotic patients (34). Accordingly, increased plasma norepinephrine levels were 
associated with the shift of the RBF/RPP relationship in cirrhosis (11). Here we 
observed that albumin infusion significantly decreased plasma norepinephrine 
levels, and therefore this could be a potential mechanism underlying the shift of 
the autoregulation curve. Amelioration in the compensatory mechanisms following 
albumin infusion reflected by the decrease in the norepinephrine levels could 
potentially explain the decrease in cardiac output documented in the AKI group. 
 
 
19 
Another factor contributing to this finding is that the second hemodynamic 
assessment took place 4-6 days after initiating albumin treatment suggesting that 
the increase in the CO post-albumin infusion could be maximum within the first 
hours decreasing thereafter (35, 36). 
RBF autoregulation is complex and involves several mechanisms and 
mediators. Endothelial cells are responsible for regulating blood flow to different 
organs. They are able to respond to different stimuli by producing agonists and 
antagonists in order to maintain vascular tone, regulate inflammatory cell 
adhesion, migration and inflammation (37). Endothelial cells can be activated by 
bacterial products (i.e. endotoxin)(4), inflammatory mediators such as tumour 
necrosis factor (5), reactive oxygen species (6) and activation of the renin-
angiotensin  aldosterone system (38) leading to  ED (37). It has been previously 
suggested that albumin might have positive effects on endothelial activation in 
patients with spontaneous bacterial peritonitis (14). Importantly in this study we 
observed that the improvement in RBF closely correlated with amelioration in 
endothelial activation following albumin infusion. In addition, albumin infusion was 
associated with a decrease in endotoxemia and oxidative stress markers. In this 
regard, albumin has been shown to have the ability to bind and neutralize 
endotoxin in vitro and in vivo (39). 
Taken together, the results of this study emphasize that the beneficial effects of 
albumin in improving renal function in cirrhosis is likely due to pleiotropic effects 
which considerably exceed its oncotic power. Specifically, this study points out 
that albumin may have an important role as an endothelial stabilizer in cirrhosis. 
The well-described anti-thrombotic effects of albumin in the microvasculature 
could also possibly explain this beneficial effect (40). Moreover, albumin infusion 
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seems to be safe, since no significant side effects were observed. One of the 
potential side effects would be worsening in portal hypertension. In contrast to our 
expectation, in the AKI group a decrease in the HVPG was documented. The 
increase in SVR with a subsequent decrease in the splanchnic blood flow could 
contribute to this observation. Nevertheless, this results support the safety profile 
of albumin infusion regarding the risk of albumin precipitating an episode of 
variceal bleeding but this observation need to be confirmed in a larger cohort of 
patients. Another potential side effect would be clinical events related to overload 
specially in high-risk population. In our cohort the increased in CVP was not 
associated to major side effects, suggesting that a well selected population and 
close monitoring can minimize the risk. 
This study has several limitations, which should be considered in interpreting 
the results of this study. On one hand we lack a control group with other plasma 
expander and therefore it is difficult to extrapolate these results. However, albumin 
infusion has been previously evaluated in controlled trials. Our observations here 
replicate the findings of these studies and explore the mechanisms underlying its 
clinical benefit. On the other hand, although this study support the role of albumin 
as an endothelial stabilizer, and suggest that it would be related through its 
capacity of neutralizing endotoxin and moderating oxidative stress, the specific 
mechanisms are still not fully clarified. In addition, the small sample size limits the 
strength of this work, but this is partly counteracted by the replication of results 
documented in larger cohorts. 
In conclusion, this study enhances our understanding of the pathophysiological 
mechanisms by which albumin infusion improves renal dysfunction in cirrhosis and 
particularly in patients acutely decompensated who have superimposed 
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inflammatory insult. Our results point out an important role for albumin as an 
endothelial stabilizer among other functions resulting in improvement in RBF 
autoregulation, which contributes to an improvement in renal function justifying a 
suitable clinical trial. 
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Tables 
Table 1. Basal clinical and biochemical characteristics of patients 
 Refractory Ascites 
(n=12) 
Acute Kidney Injury 
(n=10) 
p 
Age (years) 59.8±10.9 56.5±13.9 0.54 
Sex 
 Male 
 Female 
 
9 (75%) 
3 (25%) 
 
6 (60%) 
4 (40%) 
0.65 
Aetiology of cirrhosis 
 ALD 
 HCV 
 PBC 
 NASH 
 
6 (50%) 
3 (25%) 
2 (17%) 
1 (8%) 
 
7 (70%) 
2 (20%) 
1 (10%) 
0 
0.70 
BMI 24.3 23.4 0.65 
Child’s score 11(10-13) 14(13-14)  <0.0001 
Precipitating event 
 Alc hep 
 Infection 
none 
- 
- 
 
7 (70%) 
3 (30%) 
<0.0001 
Albumin (mg/mL) 26.5±4.1 22.3±2.9  0.01 
Bilirubin (μmol/L) 67.5±27.5 293±188.5  0.0005 
Protrombine time (sec)  16.9±2.6 21.8±3.7  0.002 
MELD 14.7±2.3 30±5.4  <0.0001 
 
Results are expressed as mean±SD, median (interquartile range) and N(%) 
*p values were assessed by χ
2
,  Fisher´s exact test, t-test or Mann Whitney test. 
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Table 2. Biochemical and humoral changes after albumin infusion 
 
Refractory Ascites Acute Kidney Injury 
Before After Before After 
Creatinine (μmol/L) 94.8±13.3 83.6±12.6** 213±60.3 154.4±42** 
Clearance Creatinine (mL/min) 29.3±7.1 41.1±10.9*** 13±4.2 28.3±10.3*** 
Urea (mmol/L) 4.8±2.6 4.1±1.9 13.2±3.4 10.7±3.4*** 
Albumin (g/L) 26.5±4.1 29.3±4.2** 22.3±2.9 26.7±3.5*** 
IMAR  0.019(0.006) 0.011(0.004)** 0.026(0.009) 0.021(0.008)** 
Bilirubin (μmol/L) 67.5±27.5 75.2±27.5*** 293±188.5 330.2±201.1* 
Serum Sodium (mEq/L) 127.8±3.2 130.6±3*** 133.4±4.2 134.6±3.8 
Urinary Sodium 24h (mmol/L) 15.8±4.6 25.5±6.1*** 8.3±4.6 15.3±7.2** 
Norepinephrine (nmol/L) 3.6±0.5 2.6±0.6*** 8.2±2.1 5.3±1.3*** 
IL-6 (pg/mL) 0.02(0.01) 0.01(0.01) 0.04(0.09) 0.02(0.07) 
Neutrophil burst (%) 37±13 25±11** 52±20 36±12** 
vWF (U/dL) 342.3±67.9 280.3±68.8*** 463.0±72.8 372.9±52.5** 
Nitrate (µmol/L) 41.6±18.2 28.9±10.2** 81.8±26.3 56.5±23.0** 
Nitrite (µmol/L) 3.6±1.2 2.9±0.9* 8.4±2.1 6.5±1.2** 
MDA (µmol/L) 6.7±3.4 4.2±1.4** 6.7±2.1 4.9±1.5** 
F2a (pg/mL) 255.0±64 181.2±47.5 403.3±227 275.2±117.8* 
 
Results are expressed in mean±SD or median(interquartile range) 
*p<0.05, **p<0.01, ***p<0.001, paired samples t-test or Wilcoxon matched pairs test 
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Table 3. Changes in cardiac, hepatic and renal hemodynamics after albumin infusion 
 
Refractory Ascites Acute Kidney Injury 
Before After Before After 
Cardiac hemodynamics 
     Heart rate (beats/min) 
     Mean arterial pressure (mmHg) 
     Central venous pressure (mmHg) 
     Cardiac output (L/min) 
     Systemic vascular resistance (dynes/s/cm
5
) 
 
85±10 
83±3 
7.6±2.4 
7.8(1.1) 
759(146) 
 
81±8** 
86±5* 
9.1±2.1* 
7.8(0.9) 
780(62) 
 
99±9 
69±3 
10.6±2.4 
9.2(3.1) 
498(188) 
 
88±9*** 
72±4* 
14.2±2.3*** 
7.4(2.5)** 
627(292)** 
Hepatic hemodynamics 
     HVPG (mmHg) 
 
19.5±2.0 
 
19.3±2.3 
 
22.2±3 
 
19.6±2.9*** 
Renal hemodynamics 
     Renal perfusion pressure (mmHg) 
     Renal Blood Flow (mL/min) 
 
73.3±3.4 
560±40 
 
77±5.3** 
695±57*** 
 
63.5±5.6 
277±49 
 
66.4±5.1 
430±81*** 
 
Results are expressed in mean±SD or median(interquartile range) 
*p<0.05, **p<0.01, ***p<0.001, paired samples t-test or Wilcoxon matched pairs test 
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Figure legends 
Figure 1: Assessment of renal blood flow. Clinical measurements along with 
theoretical autoregulation curves obtained for each patient group. Best-fit values 
for α were: α = 8.9 and α = 5.6 in groups with refractory ascites pre and post 
albumin infusion, and α = 18.44, α = 12.05 in patients with AKI pre and post 
albumin. A decrease in the value of α post albumin treatment indicates an 
improved state. Open square (☐): refractory ascites, cross (+): refractory ascites 
post albumin, open circle (o): AKI, star (*): AKI post albumin.  
 
Figure 2:. Modification in markers of endothelial activation (vWF) and endothelial 
dysfunction (nitrate/nitrite). Albumin infusion was associated to a significant 
decrease in plasma level of von-Willebrand factor and nitrate/nitrite denoting an 
improvement in endothelial activation and dysfunction. 
 
Figure 3: Correlation between improvement in endothelial activation and RBF 
following albumin infusion: The more pronounced the improvement in the 
endothelial activation, the greater the increase in the RBF. 
 
Figure 4: Changes in markers of oxidative stress (MDA, F2 alpha -free 8-
isoprostane F2-) in both groups of patients following albumin infusion. Patients 
with refractory ascites (RA) showed a decreased in MDA whereas patient with AKI 
had a reduction in plasma levels of both markers. 
